NCT06429566View on ClinicalTrials.gov

Safety and Efficacy Study of GB001 Recombinant Peptide Spray in Subjects With Mild Recurrent Aphthous Ulcers

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

July 18, 2023

Primary Completion Date

December 6, 2023

Study Completion Date

July 10, 2026

Conditions
Healthy
Interventions
DRUG

GB001 recombinant peptide spray low dose group、high dose group

Administrated oral spray. Each subject will take oral GB001 recombinant peptide spray 4 times a day, 4 sprays each time, no more than 29 times，The dosage of the group is 0.108mg/spray for low dose group and 0.216mg/spray for high dose group.

DRUG

GB001 recombinant peptide spray placebo

Administrated oral spray.Each subject will take oral GB001 recombinant peptide spray placebo 4 times a day, 4 sprays each time, no more than 29 times

Trial Locations (1)

410000

The First Hospital of Hunan University of Chinese Medicine, Changsha

All Listed Sponsors
lead

Zhejiang Echon Biopharm Limited

INDUSTRY